Dr. Michel Janicot holds a Ph.D. degree in Biochemistry (Molecular and Cellular Biology) from the University of Paris VII (France) after which he was Postdoctoral Fellow at The Johns Hopkins University (Baltimore, MD. USA). Dr. Janicot has over 25 years hands-on experience in preclinical and early clinical pharmaceutical drug development in increasing leadership roles at Rhone-Poulenc Rorer (Sanofi) and subsequently at Janssen (Johnson & Johnson).
Since 2012, Dr. Janicot is the founder and Managing Director of JMi ONConsulting, a firm specialized in providing consulting services and guidances for R&D programs in the field of Oncology, Inflammation, Immunology, Fibrosis and Ophthalmology. Under this business umbrella, Dr. Janicot is part-time management team member (acting CSO/CDO) in various companies. He is also co-founder and Board member of aPODD, a non-profit foundation focusing on Pediatric Oncology Drug Development.
Novel model for corneal permeability in vitro testing through the combined use of collagen-based hydrogels with stratified corneal epithelial cells
A synthetic metalloporphyrin SOD mimetic protects corneal epithelial cells from oxidative stress-induced damage in vitro and in vivo
Subscribe to Our Newsletter!
We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!